Table 3.
Histomorphometric parameters in stroke patients vs. healthy controls [mean (SD)]
| Measurement | n | All Stroke Pts | n | Controls | p Value | ||
|---|---|---|---|---|---|---|---|
| Age range | 56–89 | 51–80 | |||||
| Sex | 3f, 11m | 16f, 12m | |||||
| BV/TV (%) | 14 | 19.6 (4.6) | 28 | 22.3 (4.3) | 0.065 | ||
| O.Th (um) | 14 | 6.5 (1.1) | 28 | 6.1 (2.1) | 0.537 | ||
| ES/BS (%) | 14 | 5.7 (1.7) | 28 | 1.6 (0.7) | < 0.0001a | ||
| MS/BS (%) | 11 | 1.6 (1.3)c | 28 | 11.1 (5.5) | < 0.0001a | ||
| MAR (um/d) | 11 | 0.6 (0.3)d | 28 | 0.6 (0.1) | 0.454 | ||
| Zol | Pla | ||||||
| OS/BS (%) | 5 | 9 | 7.7 (3.9) | 3.0 (1.7) | 28 | 27.8 (11.8) | < 0.05b |
| OV/BV (%) | 5 | 9 | 1.0 (0.6) | 0.3 (0.2) | 28 | 4.0 (2.2) | < 0.05b |
| W.Th (um) | 5 | 9 | 32.0 (4.0) | 28.3 (3.4) | 28 | 34.9 (3.0) | < 0.05b |
a
Significantly different from control mean by 2 sided t-test.
b
Significantly different from control mean by Dunnett's test.
c
Includes zero values from 1 zoledronate patient (no labels present) and from 2 placebo patients (single cortical labels).
d
Includes assumed MAR of 0.3 um/d in 2 placebo patients with only single cortical labels (Foldes method).